Top

Published in:

01-12-2020 | NSCLC | Research

Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial

Authors: Rea Bingula, Edith Filaire, Ioana Molnar, Eve Delmas, Jean-Yves Berthon, Marie-Paule Vasson, Annick Bernalier-Donadille, Marc Filaire

Published in: Respiratory Research | Issue 1/2020

Abstract

Background

While well-characterised on its molecular base, non-small cell lung cancer (NSCLC) and its interaction with local microbiota remains scarcely explored. Moreover, current studies vary in source of lung microbiota, from bronchoalveolar lavage fluid (BAL) to tissue, introducing potentially differing results. Therefore, the objective of this study was to provide detailed characterisation of the oral and multi-source lung microbiota of direct interest in lung cancer research. Since lung tumours in lower lobes (LL) have been associated with decreased survival, characteristics of the microbiota in upper (UL) and lower tumour lobes have also been examined.

Methods

Using 16S rRNA gene sequencing technology, we analysed microbiota in saliva, BAL (obtained directly on excised lobe), non-malignant, peritumoural and tumour tissue from 18 NSCLC patients eligible for surgical treatment. Detailed taxonomy, diversity and core members were provided for each microbiota, with analysis of differential abundance on all taxonomical levels (zero-inflated binomial general linear model with Benjamini-Hochberg correction), between samples and lobe locations.

Results

Diversity and differential abundance analysis showed clear separation of oral and lung microbiota, but more importantly, of BAL and lung tissue microbiota. Phylum Proteobacteria dominated tissue samples, while Firmicutes was more abundant in BAL and saliva (with class Clostridia and Bacilli, respectively). However, all samples showed increased abundance of phylum Firmicutes in LL, with decrease in Proteobacteria. Also, clades Actinobacteria and Flavobacteriia showed inverse abundance between BAL and extratumoural tissues depending on the lobe location. While tumour microbiota seemed the least affected by location, peritumoural tissue showed the highest susceptibility with markedly increased similarity to BAL microbiota in UL. Differences between the three lung tissues were however very limited.

Conclusions

Our results confirm that BAL harbours unique lung microbiota and emphasise the importance of the sample choice for lung microbiota analysis. Further, limited differences between the tissues indicate that different local tumour-related factors, such as tumour type, stage or associated immunity, might be the ones responsible for microbiota-shaping effect. Finally, the “shift” towards Firmicutes in LL might be a sign of increased pathogenicity, as suggested in similar malignancies, and connected to worse prognosis of the LL tumours.

Trial registration

ClinicalTrials.gov ID: NCT03068663. Registered February 27, 2017.

Available only for authorised users

Stewart BW, Wild CP. World cancer report 2014. 2014th ed. Lyon: International Agency for Research on Cancer; 2014. doi:9283204298.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009.CrossRefPubMed

Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46–52. https://doi.org/10.1097/JTO.0b013e31815e8577.CrossRefPubMed

Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg. 2004;127:1100–6. https://doi.org/10.1016/j.jtcvs.2003.09.012.CrossRefPubMed

Hayakawa K, Mitsuhashi N, Saito Y, Furuta M, Nakayama Y, Katano S, et al. Impact of tumor extent and location on treatment outcome in patients with stage III non-small cell lung cancer treated with radiation therapy. Jpn J Clin Oncol. 1996;26:221–8. https://doi.org/10.1093/oxfordjournals.jjco.a023218.CrossRefPubMed

Ou S-HHI, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 Stage I patients in the California cancer registry from 1989 to 2003. Cancer. 2007;110:1532–41. https://doi.org/10.1002/cncr.22938.CrossRefPubMed

Goldszmid RS, Dzutsev A, Viaud S, Zitvogel L, Restifo NP, Trinchieri G. Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunol Res. 2015;3:103–9. https://doi.org/10.1158/2326-6066.CIR-14-0225.CrossRefPubMedPubMedCentral

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–9. https://doi.org/10.1126/science.aac4255.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. https://doi.org/10.1126/science.aan3706.CrossRefPubMed

10.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 2016;45:931–43. https://doi.org/10.1016/j.immuni.2016.09.009.

11.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6. https://doi.org/10.1126/science.1240537.CrossRefPubMedPubMedCentral

12.

Viaud S, Daillère R, Boneca IG, Lepage P, Langella P, Chamaillard M, et al. Gut microbiome and anticancer immune response: really hot Sh*t! Cell Death Differ. 2015;22:199–214. https://doi.org/10.1038/cdd.2014.56.CrossRefPubMed

13.

Bingula R, Filaire M, Radosevic-Robin N, Bey M, Berthon J-Y, Bernalier-Donadille A, et al. Desired turbulence? Gut-lung axis, immunity, and lung cancer. J Oncol. 2017;2017:1–15. https://doi.org/10.1155/2017/5035371.CrossRef

14.

Jobin C. Precision medicine using microbiota. Science. 2018;359:32–4. https://doi.org/10.1126/science.aar2946.CrossRefPubMed

15.

Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014;2:238–46. https://doi.org/10.1016/S2213-2600(14)70028-1.CrossRefPubMedPubMedCentral

16.

Marsland BJ, Gollwitzer ES. Host–microorganism interactions in lung diseases. Nat Rev Immunol. 2014;14:827–35. https://doi.org/10.1038/nri3769.CrossRefPubMed

17.

Bernasconi E, Pattaroni C, Koutsokera A, Pison C, Kessler R, Benden C, et al. Airway microbiota determines innate cell inflammatory or tissue remodeling profiles in lung transplantation. Am J Respir Crit Care Med. 2016;194:1252–63. https://doi.org/10.1164/rccm.201512-2424OC.CrossRefPubMed

18.

Blainey PC, Milla CE, Cornfield DN, Quake SR. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. Sci Transl Med. 2012;4:153ra130. https://doi.org/10.1126/scitranslmed.3004458.CrossRefPubMedPubMedCentral

19.

Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, Huffnagle GB, et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc. 2015;12:821–30. https://doi.org/10.1513/AnnalsATS.201501-029OC.CrossRefPubMedPubMedCentral

20.

Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384:691–702. https://doi.org/10.1016/S0140-6736(14)61136-3.

21.

Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1073–80. https://doi.org/10.1164/rccm.201111-2075OC.CrossRefPubMedPubMedCentral

22.

Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5:e8578. https://doi.org/10.1371/journal.pone.0008578.CrossRefPubMedPubMedCentral

23.

Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell. 2019;176:998–1013. https://doi.org/10.1016/j.cell.2018.12.040.CrossRefPubMedPubMedCentral

24.

Cheng M, Qian L, Shen GGG, Bian G, Xu T, Xu W, et al. Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism. Cancer Res. 2014;74:4030–41. https://doi.org/10.1158/0008-5472.CAN-13-2462.CrossRefPubMed

25.

Boursi B, Mamtani R, Haynes K, Yang Y-X. Recurrent antibiotic exposure may promote cancer formation – another step in understanding the role of the human microbiota? Eur J Cancer. 2015;51:2655–64. https://doi.org/10.1016/j.ejca.2015.08.015.CrossRefPubMedPubMedCentral

26.

Segal LN, Clemente JC, Tsay J-CJ, Koralov SB, Keller BC, Wu BG, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol. 2016;1:16031. https://doi.org/10.1038/nmicrobiol.2016.31.CrossRefPubMedPubMedCentral

27.

Segal LN, Clemente JC, Tsay J-CJ, Koralov SB, Keller BC, Wu BG, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome. 2013;1:19. https://doi.org/10.1186/2049-2618-1-19.CrossRefPubMedPubMedCentral

28.

Tsay JCJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, et al. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med. 2018;198:1188–98. https://doi.org/10.1164/rccm.201710-2118OC.CrossRefPubMedPubMedCentral

29.

Wang K, Huang Y, Zhang Z, Liao J, Ding Y, Fang X, et al. A preliminary study of microbiota diversity in saliva and bronchoalveolar lavage fluid from patients with primary bronchogenic carcinoma. Med Sci Monit. 2019;25:2819–34. https://doi.org/10.12659/msm.915332.CrossRefPubMedPubMedCentral

30.

Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer. 2018;142:769–78. https://doi.org/10.1002/ijc.31098.

31.

Yan X, Yang M, Liu J, Gao R, Hu J, Li J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res. 2015;5:3111–22 http://www.ncbi.nlm.nih.gov/pubmed/26693063. Accessed 25 Sep 2019.PubMedPubMedCentral

32.

Yu G, Gail MH, Consonni D, Carugno M, Humphrys M, Pesatori AC, et al. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol. 2016;17:163. https://doi.org/10.1186/s13059-016-1021-1.CrossRefPubMedPubMedCentral

33.

Peters BA, Hayes RB, Goparaju C, Reid C, Pass HI, Ahn J. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemiol Biomark Prev. 2019;28:731–40. https://doi.org/10.1158/1055-9965.EPI-18-0966.CrossRef

34.

Bingula R, Filaire M, Radosevic-Robin N, Berthon J-Y, Bernalier-Donadille A, Vasson M-P, et al. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma. Medicine. 2018;97:e13676. https://doi.org/10.1097/MD.0000000000013676.CrossRefPubMedPubMedCentral

35.

RStudio Team. RStudio: integrated development environment for R. 2016. http://www.rstudio.com/.

36.

McMurdie PJ, Holmes S. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8:e61217. https://doi.org/10.1371/journal.pone.0061217.CrossRefPubMedPubMedCentral

37.

Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, Mcglinn D, et al. vegan: Community ecology package. 2019. https://cran.r-project.org/web/packages/vegan/vegan.pdf. Accessed 6 Jun 2019.

38.

Lahti L, Shetty S, Blake T, Salojarvi J. microbiome R package. 2017. http://microbiome.github.io.

39.

Wickham H. ggplot2: Elegant graphics for data analysis. 2016. http://ggplot2.org.

40.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.CrossRefPubMedPubMedCentral

41.

Foster ZSL, Sharpton TJ, Grünwald NJ. Metacoder: an R package for visualization and manipulation of community taxonomic diversity data. PLoS Comput Biol. 2017;13:e1005404. https://doi.org/10.1371/journal.pcbi.1005404.

42.

Dickson RP, Cox MJ. Gut microbiota and protection from pneumococcal pneumonia. Gut. 2017;66:384. https://doi.org/10.1136/gutjnl-2016-311823.CrossRefPubMed

43.

Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J COPD. 2014;9:229–38. https://doi.org/10.2147/COPD.S38932.CrossRef

44.

Vital M, Harkema JR, Rizzo M, Tiedje J, Brandenberger C. Alterations of the murine gut microbiome with age and allergic airway disease. J Immunol Res. 2015;2015:1–8. https://doi.org/10.1155/2015/892568.CrossRef

45.

Dickson RP, Erb-Downward JR, Freeman CM, Walker N, Scales BS, Beck JM, et al. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS One. 2014;9:e97214. https://doi.org/10.1371/journal.pone.0097214.CrossRefPubMedPubMedCentral

46.

Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One. 2012;7:e45001. https://doi.org/10.1371/journal.pone.0045001.

47.

Lee SH, Sung JY, Yong D, Chun J, Kim SKSSY, Song JH, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer. 2016;102:89–95. https://doi.org/10.1016/j.lungcan.2016.10.016.CrossRefPubMed

48.

Dickson RP, Erb-downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, et al. Cell-associated bacteria in the human lung microbiome. Microbiome. 2014;2:1–10. https://doi.org/10.1186/2049-2618-2-28.

49.

Snoeckx A, Dendooven A, Carp L, Desbuquoit D, Spinhoven MJ, Lauwers P, et al. Wolf in sheep’s clothing: primary lung cancer mimicking benign entities. Lung Cancer. 2017;112:109–17. https://doi.org/10.1016/j.lungcan.2017.07.037.CrossRefPubMed

50.

Busch SE, Hanke ML, Kargl J, Metz HE, MacPherson D, Houghton AM. Lung cancer subtypes generate unique immune responses. J Immunol. 2016;197:4493–503. https://doi.org/10.4049/jimmunol.1600576.CrossRefPubMed

51.

Valkenburg KC, De Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366–81. https://doi.org/10.1038/s41571-018-0007-1.CrossRefPubMedPubMedCentral

52.

Charlson ES, Bittinger K, Chen J, Diamond JM, Li H, Collman RG, et al. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS One. 2012;7:e42786. https://doi.org/10.1371/journal.pone.0042786.

53.

Grassl N, Kulak NA, Pichler G, Geyer PE, Jung J, Schubert S, et al. Ultra-deep and quantitative saliva proteome reveals dynamics of the oral microbiome. Genome Med. 2016;8:44. https://doi.org/10.1186/s13073-016-0293-0.CrossRefPubMedPubMedCentral

54.

Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio. 2015;6:1–10. https://doi.org/10.1128/mBio.00037-15.

55.

Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest. 1997;111:1266–72. https://doi.org/10.1378/chest.111.5.1266.CrossRefPubMed

56.

Anesti V, McDonald IR, Ramaswamy M, Wade WG, Kelly DP, Wood AP. Isolation and molecular detection of methylotrophic bacteria occurring in the human mouth. Environ Microbiol. 2005;7:1227–38. https://doi.org/10.1111/j.1462-2920.2005.00805.x.CrossRefPubMed

57.

Jamieson WD, Pehl MJ, Gregory GA, Orwin PM. Coordinated surface activities in Variovorax paradoxus EPS. BMC Microbiol. 2009;9:124. https://doi.org/10.1186/1471-2180-9-124.

58.

Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017;15:740–55. https://doi.org/10.1038/nrmicro.2017.99.CrossRefPubMedPubMedCentral

59.

Riquet M, Pricopi C, Arame A, Barthes FLP. From anatomy to lung cancer: questioning lobe-specific mediastinal lymphadenectomy reliability. J Thorac Dis. 2016;8:2387–90. https://doi.org/10.21037/jtd.2016.08.90.CrossRefPubMedPubMedCentral

60.

Kotoulas CS, Foroulis CN, Kostikas K, Konstantinou M, Kalkandi P, Dimadi M, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer. 2004;44:183–91. https://doi.org/10.1016/j.lungcan.2003.10.012.CrossRefPubMed

61.

Mukerji R, Kakarala R, Smith SJ, Kusz HG. Chryseobacterium indologenes: an emerging infection in the USA. BMJ Case Rep. 2016;2016:bcr2016214486. https://doi.org/10.1136/bcr-2016-214486.CrossRefPubMedPubMedCentral

62.

Purty S, Saranathan R, Prashanth K, Narayanan K, Asir J, Sheela Devi C, et al. The expanding spectrum of human infections caused by Kocuria species: a case report and literature review. Emerg Microbes Infect. 2013. https://doi.org/10.1038/emi.2013.71.

63.

Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7:e47305. https://doi.org/10.1371/journal.pone.0047305.CrossRefPubMedPubMedCentral

64.

Savini V, Gherardi G, Astolfi D, Polilli E, Dicuonzo G, D’Amario C, et al. Insights into airway infections by enterococci: a review. Recent Pat Antiinfect Drug Discov. 2012;7:36–44. https://doi.org/10.2174/157489112799829774.

65.

Werner JL, Escolero SG, Hewlett JT, Mak TN, Williams BP, Eishi Y, et al. Induction of pulmonary granuloma formation by propionibacterium acnes is regulated by MyD88 and Nox2. Am J Respir Cell Mol Biol. 2017;56:121–30. https://doi.org/10.1165/rcmb.2016-0035OC.CrossRefPubMedPubMedCentral

66.

Henao-Martínez AF, González-Fontal GR, Castillo-Mancilla JR, Yang IV. Enterobacteriaceae bacteremias among cancer patients: an observational cohort study. Int J Infect Dis. 2013;17:e374–8. https://doi.org/10.1016/j.ijid.2012.11.030.CrossRefPubMedPubMedCentral

67.

Bhat R, Bissell MJ. Of plasticity and specificity: dialectics of the microenvironment and macroenvironment and the organ phenotype. Wiley Interdiscip Rev Dev Biol. 2014;3:147–63. https://doi.org/10.1002/wdev.130.CrossRefPubMed

68.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37. https://doi.org/10.1038/nm.3394.CrossRefPubMedPubMedCentral

69.

Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320–9. https://doi.org/10.1038/nm.2328.CrossRefPubMedPubMedCentral

70.

Altinay S. Is extracellular matrix a castle against to invasion of cancer cells? In: Tumor metastasis. London: IntechOpen; 2016. https://doi.org/10.5772/64495.

71.

Wouters BG, Koritzinsky M, Chiu RK, Theys J, Buijsen J, Lambin P. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol. 2003;13:31–41. https://doi.org/10.1053/srao.2003.50004.CrossRefPubMed

72.

Fadaka A, Ajiboye B, Ojo O, Adewale O, Olayide I, Emuowhochere R. Biology of glucose metabolization in cancer cells. J Oncol Sci. 2017;3:45–51. https://doi.org/10.1016/j.jons.2017.06.002.CrossRef

73.

Bagheri R, Haghi SZ, Dalouee MN, Nasiri Z, Rajabnejad A. Evaluation of the results of surgery treatment in patients with benign lung tumors. Lung India. 2015;32:29–33. https://doi.org/10.4103/0970-2113.148436.

74.

Khan A, Al-Jahdali H, Irion K, Arabi M, Koteyar S. Solitary pulmonary nodule: a diagnostic algorithm in the light of current imaging technique. Avicenna J Med. 2011;1:39-51. https://doi.org/10.4103/2231-0770.90915.

75.

Kalchiem-Dekel O, Galvin J, Burke A, Atamas S, Todd N. Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J Clin Med. 2018;7:476. https://doi.org/10.3390/jcm7120476.

76.

Luh SP. Diagnosis and treatment of primary spontaneous pneumothorax. J Zhejiang Univ Sci B. 2010;11:735–44. https://doi.org/10.1631/jzus.B1000131.

77.

Dimakou K, Chrysikos S, Melachroinidou M, Triantafillidou C. Bronchiectasis and emphysema. Pneumon. 2016;29:334–7.

78.

Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One. 2011;6:e16384. https://doi.org/10.1371/journal.pone.0016384.CrossRefPubMedPubMedCentral

79.

Wild CP, Weiderpass E, Stewart BW. World cancer report: cancer research for cancer prevention. 2020th ed. Lyon: International Agency for Research on Cancer; 2020. http://publications.iarc.fr/586.

Title: Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial
Authors: Rea Bingula
Edith Filaire
Ioana Molnar
Eve Delmas
Jean-Yves Berthon
Marie-Paule Vasson
Annick Bernalier-Donadille
Marc Filaire
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Respiratory Microbiota
Lung Cancer
Published in: Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/s12931-020-01392-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease

Construction of asthma related competing endogenous RNA network revealed novel long non-coding RNAs and potential new drugs

Extracorporeal membrane oxygenation as a bridge to lung transplantation: analysis of Korean organ transplantation registry (KOTRY) data

Could KL-6 levels in COVID-19 help to predict lung disease?

Neuromuscular blocking agents for acute respiratory distress syndrome: an updated meta-analysis of randomized controlled trials

Bacteria and sputum inflammatory cell counts; a COPD cohort analysis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage